Target-Ag® Platform for Allergic Disease Vaccines
Creative Biolabs is more than just a CRO company that only provides vaccine development support services. We are also actively absorbing the best vaccine researchers from around the world and leveraging their talents and years of experience of our own. Therefore, we are able to launch a series of high efficient vaccine platforms that can be adapted to the different needs of customers.
Call for Allergic Disease Vaccine
As a typical representative of allergic diseases, allergic asthma is a chronic airway inflammation involving a variety of cells, particularly mast cells, eosinophils, and T lymphocytes, and the airway is highly reactive toward various stimuli. In the past ten years, the prevalence and mortality rates of asthma in the United Kingdom, the United States, Australia, and New Zealand have increased. There are about 100 million asthma patients in the world, which has become a major chronic threat to public health. Therefore, the development of vaccines for allergic diseases, especially allergic asthma, is born in huge market demand. A universal and effective allergy disease vaccine development platform is also particularly warmly welcomed by the market.
Target-Ag® - A Versatile Vaccine Platform for Both Allergic Diseases and Cancers
The launch of the Target-Ag® platform is due to this demand. However, after continuous improvement and optimization, Target-Ag® can now be used for the development of various allergic disease vaccines, and the application of the platform can also be extended to the development of cancer vaccines as long as the appropriate antigen is selected. Target-Ag® consists of two components, one of which is the antigen-presenting cell targeting module, which allows vaccines to specifically bind to professional antigen-presenting cells (APCs), and promotes APCs’ uptake of vaccines, and stimulates APCs to produce a large number of Th1-inducing cytokines through interaction with TLR9, exerting an endogenous adjuvant effect. Another part of Target-Ag® is the antigen module, which is connected to targeting module through a linker with high affinity. It is worth noting that the Target-Ag® antigen module consists of disrupted allergen-specific Th1 cell epitopes, which are designed to not only stimulate immune protection against allergens, but also to avoid interactions between allergens with allergen-specific IgE (which may lead to the occurrence of anaphylactic shock). Besides incorporating allergen-specific Th1 cell epitopes in antigen module, tumor-associated antigen or neoantigens of cancers can also be consisted in the Target-Ag® to prepare a cancer vaccine.
Creative Biolabs' more than a decade of hard work in the vaccine industry has now yielded fruitful results - we have launched a range of high-quality technology platforms that help our customers better develop vaccines. The concept of Target-Ag® can be applied to the development of allergic vaccines and cancer vaccines. A number of experimental results validate the effectiveness of this platform, if you want to know more about this, please contact us!
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
